Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile

Gastroenterology. 2021 Feb;160(3):941-945.e8. doi: 10.1053/j.gastro.2020.10.046. Epub 2020 Nov 14.

Abstract

The increasing incidence of primary and recurring Clostridioides difficile infections (CDI), which evade current treatment strategies, reflects the changing biology of C difficile. Here, we describe a putative plasmid-mediated mechanism potentially driving decreased sensitivity of C difficile to vancomycin treatment. We identified a broad host range transferable plasmid in a C difficile strain associated with lack of adequate response to vancomycin treatment. The transfer of this plasmid to a vancomycin-susceptible C difficile isolate decreased its susceptibility to vancomycin in vitro and resulted in more severe disease in a humanized mouse model. Our findings suggest plasmid acquisition in the gastrointestinal tract to be a possible mechanism underlying vancomycin treatment failure in patients with CDI, but further work is needed to characterize the mechanism by which plasmid genes determine vancomycin susceptibility in C difficile.

Keywords: Amidase; Antimicrobial Resistance; Cell Wall Peptidoglycan; Gram Positive.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides difficile / drug effects
  • Clostridioides difficile / genetics*
  • Clostridioides difficile / isolation & purification
  • Clostridium Infections / drug therapy*
  • Clostridium Infections / microbiology
  • Disease Models, Animal
  • Drug Resistance, Bacterial / genetics
  • Germ-Free Life
  • Humans
  • Mice
  • Microbial Sensitivity Tests
  • Plasmids / genetics*
  • Plasmids / isolation & purification
  • Vancomycin / pharmacology*
  • Vancomycin / therapeutic use
  • Whole Genome Sequencing

Substances

  • Anti-Bacterial Agents
  • Vancomycin